{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-020181","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.344691+00:00","generated_at":"2026-06-05T04:14:31.661547+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cadrenal Therapeutics receives 180-day Nasdaq extension to Sept 3, 2024 to meet $1 bid price rule","bullets":["Nasdaq granted a 180-day extension until September 3, 2024 to regain minimum $1.00 closing bid price.","Compliance requires $1.00 bid price for at least 10 consecutive business days; can be extended up to 20 days.","Non-compliance was first disclosed on September 6, 2023; stock continues trading on Nasdaq under CVKD.","Company may consider a reverse stock split if it cannot meet the price requirement by the deadline.","If compliance not regained by Sept 3, 2024, Nasdaq will delist; company could appeal to hearings panel."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-020181","json":"https://secwatch.observer/filing/0001213900-24-020181.json","markdown":"https://secwatch.observer/filing/0001213900-24-020181.md","text":"https://secwatch.observer/filing/0001213900-24-020181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/0001213900-24-020181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/ea0201254-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:14:31.661547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"028353250ff4d3e0fe2223d603da6819cf8afabc","claim":"Cadrenal Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 5, 2024, the Company received written notification from Nasdaq granting the Company's request for a 180-day extension or until September 3, 2024 to regain compliance with the Rule. Compliance is generally achieved by meeting the minimum bid price of $1.00 per share (the “Price Requirement”) for a minimum of 10 consecutive business days. However, the Staff may, in its discretion, require a Company to satisfy the applicable Price Requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company h","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/0001213900-24-020181-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}